FDA Orange Book
Is there a generic for Journavx?
Journavx contains suzetrigine. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Journavx (suzetrigine). The Orange Book shows its last listed patent expires December 4, 2040 and its last listed exclusivity ends January 30, 2030.
Run it in Rivvi
Map Journavx and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Journavx products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| tablet, oral | 50MG | Marketed (Rx) | None | 0 | None |
NDA 219209, held by VERTEX PHARMACEUTICALS INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Journavx patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 11834441 | December 4, 2040 | Drug substance, Drug product | U-4125 | 219209 |
Journavx exclusivity
| Code | Meaning | Expires | NDA |
|---|---|---|---|
| NCE | New chemical entity | January 30, 2030 | 219209 |
Journavx NDC codes
Questions
Is there a generic for Journavx?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Journavx (suzetrigine). The Orange Book shows its last listed patent expires December 4, 2040 and its last listed exclusivity ends January 30, 2030.
What is the generic name for Journavx?
The active ingredient in Journavx is suzetrigine, per the FDA Orange Book.
When does the Journavx patent expire?
The last patent listed for Journavx in the Orange Book expires December 4, 2040. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.